Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from BioInvent International AB ( (SE:BINV) ).
BioInvent International, a Lund-based clinical-stage biotech specializing in immuno-modulatory antibodies for cancer, is advancing drug candidates for both blood cancers and solid tumors using its proprietary F.I.R.S.T. discovery platform. The company monetizes its technology through partnerships, licensing deals and third-party antibody production, reinforcing its position in the oncology biologics market.
BioInvent will present new clinical data at the EHA 2026 Congress on its FcγRIIB antibody BI-1206 in a triplet regimen with rituximab and AstraZeneca’s BTK inhibitor Calquence for relapsed or refractory non-Hodgkin’s lymphoma, including follicular lymphoma. The Phase 1/2 study’s Phase 2a arm, which has completed enrolment of about 30 patients, has already shown an 80% objective response rate and 100% disease control with favorable tolerability, underscoring the potential of BI-1206 to overcome resistance to rituximab and strengthen BioInvent’s position in hematology oncology collaborations.
The most recent analyst rating on (SE:BINV) stock is a Buy with a SEK90.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a Swedish clinical-stage biotech company focused on discovering and developing first-in-class immuno-modulatory antibodies for cancer therapy, with candidates in Phase 1/2 trials targeting hematological malignancies and solid tumors. Its proprietary F.I.R.S.T. platform identifies both novel targets and matching antibodies, supporting its own pipeline and generating licensing and research collaborations with multiple top-tier pharmaceutical partners while also providing antibody manufacturing services.
Average Trading Volume: 101,858
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.52B
Learn more about BINV stock on TipRanks’ Stock Analysis page.